Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.020
0.00 (0.00%)
At close: May 22, 2026, 4:00 PM EDT
1.000
-0.020 (-1.96%)
After-hours: May 22, 2026, 6:28 PM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 194 employees as of December 31, 2025. The number of employees increased by 13 or 7.18% compared to the previous year.
Employees
194
Change (1Y)
13
Growth (1Y)
7.18%
Revenue / Employee
$1,197,959
Profits / Employee
-$105,727
Market Cap
273.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 194 | 13 | 7.18% | 194 | 0 |
| Dec 31, 2024 | 181 | 14 | 8.38% | 181 | 0 |
| Dec 31, 2023 | 167 | -38 | -18.54% | 167 | 0 |
| Dec 31, 2022 | 205 | -221 | -51.88% | 204 | 1 |
| Dec 31, 2021 | 426 | 46 | 12.11% | 426 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aurora Cannabis | 1,073 |
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Lifecore Biomedical | 382 |
| Evolus | 350 |
| Anika Therapeutics | 235 |
AKBA News
- 18 days ago - Akebia Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 18 days ago - Akebia Therapeutics Earnings release: Q1 2026 - Filings
- 18 days ago - Akebia Therapeutics Quarterly report: Q1 2026 - Filings
- 18 days ago - Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - GlobeNewsWire
- 21 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology - GlobeNewsWire
- 25 days ago - Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire
- 27 days ago - Akebia Therapeutics Proxy statement: Proxy filing - Filings